Redefining How Patients Pay for Insulin
By Michelle Carnahan, Head of North America Primary Care, Sanofi
At Sanofi, we work passionately every day to better understand and address the healthcare needs of people living with diabetes. The complexities of the U.S. healthcare system have led to higher out-of-pocket costs for patients. We know that lifesaving medicines like insulin are not accessible to all who need them. As a company, we know that this is unacceptable and want to do our part to take action to bring real solutions to people living with diabetes. As mothers, fathers, daughters, sons, and many of us living with or caring for people with chronic conditions, we take this challenge seriously each and every day.
Sanofi believes that no one should struggle to pay for their insulin, regardless of their insurance status or income level. Today, we are further expanding our innovative Insulins Valyou Savings Program which will help people who are exposed to high prices at the pharmacy counter.
Starting in June, uninsured patients paying cash in the U.S. will pay only $99 per month to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month through the Insulins Valyou Savings Program. People exposed to high out-of-pocket prices at the pharmacy counter can participate in the Insulins Valyou Savings Program regardless of income level. This includes those who are paying high retail prices for their insulin and those who don’t qualify for other patient assistance programs. Since it was launched last April, the program has resulted in approximately $10 million in patient savings.
This program doesn’t take away from our long-standing commitment to support the individual needs of all of our patients. That is why we continue to offer our co-pay programs which may limit out-of-pocket expenses sometimes to $0 for all commercially insured patients regardless of income level. In addition, we provide medications, including insulin, at no charge for qualified low-income, uninsured patients through the patient assistance component of the Sanofi Patient Connection program. There is no one solution to this access and affordability puzzle, so it will take a suite of programs to support each person’s distinct needs.
As a company, we recognize that we still have a way to go to help make insulin truly accessible for every patient who relies on our medicines. Every player in our healthcare system has an important role to play in making treatment possible for everyone who needs it. Sanofi is proud to further our commitment to those living with diabetes through our Insulins Valyou Savings Program. We remain committed to listening to the voices of the patients and families who rely on our medicines and taking action to ensure our insulins are affordable for all.
*The Insulins Valyou Savings Program excludes Sanofi’s combination insulin product